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Abstract 
HPV vaccination rates in Florida are low. To increase rates, the CDC recommends clinics adhere 
to components of their evidence-based quality improvement program, AFIX (Assessment, 
Feedback, Incentives, and eXchange of information). We explored factors associated with 
engaging in HPV-specific AFIX-related activities. In 2016, we conducted a cross-sectional 
survey of a representative sample of 770 pediatric and family medicine physicians in Florida and 
assessed vaccination practices, clinic characteristics, and HPV-related knowledge. Data were 
analyzed in 2017. The primary outcome was whether physicians’ clinics engaged in ≥1 AFIX 
activity. We stratified by physician specialty and developed multivariable models using a 
backward selection approach. Of the participants in analytic sample (n=340), 52% were male, 
60% were White of any ethnicity, and 55% were non-Hispanic. Pediatricians and family 
medicine physicians differed on: years practicing medicine (p<0.001), HPV-related knowledge 
(p<0.001), and VFC provider status (p<0.001), among others. Only 39% of physicians reported 
engaging in ≥1 AFIX activity. In the stratified multivariable model for pediatricians, AFIX 
activity was significantly associated with HPV-related knowledge (aOR=1.33;95%CI=1.08-1.63) 
and provider use of vaccine reminder prompts (aOR=3.61;95%CI=1.02-12.77). For family 
medicine physicians, HPV-related knowledge was significant (aOR=1.57;95%CI=1.20-2.05) as 
was majority race of patient population (non-Hispanic White vs. Other: aOR=3.02;95%CI=1.08-
8.43), daily patient load (<20 vs. 20-24: aOR=9.05;95%CI=2.72-30.10), and vaccine 
administration to male patients (aOR=2.98;95%CI=1.11-8.02). Fewer than half of Florida 
pediatric and family medicine physicians engaged in any AFIX activities. Future interventions to 
increase AFIX engagement should focus on implementing and evaluating AFIX activities in 
groups identified as having low engagement in AFIX activities.  
 
Keywords: human papillomavirus; vaccination; cancer vaccines; adolescent health services; 
vaccination promotion; immunization programs; quality improvement programs 
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Introduction 
Over 79 million people in the U.S. are currently infected with human papillomavirus (HPV), a 
virus that causes cervical, vaginal, vulvar, anal, penile, and oropharyngeal cancers as well as 
genital warts.1 The nine-valent vaccine has the potential to prevent up to 90% of cervical cancers 
and 90% of genital warts.2 The Advisory Committee on Immunization Practices (ACIP) 
recommends two doses of the HPV vaccine for males and females ages 9-14 or three doses for 
males and females 15-26.3 Despite the potential benefits of the vaccine and the ACIP 
recommendations, uptake remains disappointingly low with only 49.5% of girls and 37.5% of 
boys in the U.S. between 13 and 17 years of age being up-to-date on their HPV vaccinations in 
2016 based on current ACIP guidelines.4 Vaccination rates in Florida are even lower for both 
girls (46.4%) and boys (34.5%).4 This is particularly concerning because Florida also has some 
of the highest rates of HPV-related disease including oropharyngeal and cervical cancers.5  
 
In an effort to increase pediatric vaccination rates, the Centers for Disease Control and 
Prevention (CDC) created a quality improvement program: Assessment, Feedback, Incentives, 
and eXchange of information (AFIX).6 AFIX is a widely accepted strategy for improving 
childhood vaccination rates7 and is a promising approach for increasing HPV vaccine coverage 
among adolescents.8 Additionally, recent data show healthcare providers who did receive an 
AFIX visit from the health department have positive attitudes with regard to these visits 
including high scores on ease of understanding, convenience, helpfulness, and facilitation.9  The 
AFIX approach incorporates four key strategies that have been shown to reliably improve 
providers’ immunization service delivery and raise vaccination coverage levels: (1) assessing the 
providers’ vaccination coverage levels; (2) giving the providers feedback of results of the 
assessment as well as strategies to improve vaccine delivery; (3) providing incentives to reward 
improved vaccination rates; and (4) exchanging information through continued follow-up with 
providers to both monitor and support progress.6 AFIX uses an “assessment and feedback” 
approach in which state and local health departments deliver vaccine quality improvement 
consultations to providers, with a particular focus on providers who are a part of the Vaccines for 
Children (VFC) federal low cost vaccination program.6 While AFIX encounters are usually 
administered by health departments to the clinics, the present study is extending the utilization of 
these quality improvement initiatives to examine provider-reported integration of the AFIX-
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based strategies specific to HPV vaccination in their clinics, regardless of whether an AFIX visit 
occurred in the clinic.  
 
Previous research demonstrates that the use of AFIX-based strategies, such as informing 
providers of their vaccination coverage, increases vaccination rates.8,9 Therefore, the present 
study aimed to identify characteristics associated with low usage of these evidence-based 
strategies in order to identify potential targets for future interventions. The objective of the 
present study was to assess Florida primary care physicians’ report of HPV-specific quality 
improvement activities aligned with the CDC’s AFIX program and determine factors associated 
with use of AFIX to identify potential areas for future intervention efforts.  
 
Methods 
Sample 
As part of an ongoing study assessing Florida-based primary care physicians’ experiences with 
HPV vaccination recommendation in clinical practice, we conducted two cross-sectional surveys 
of primary care physicians in Florida. Results of the first survey, completed in 2014, were 
focused on physician recommendation of HPV vaccination for adolescent and young adult boys, 
and have been previously published.10,11 Here we present results from the second survey, 
conducted in 2016 and analyzed in 2017, which was focused on identifying multi-level targets 
for intervention strategies to improve HPV vaccination rates. Specifically, identifying factors 
associated with low usage of HPV-specific AFIX-based strategies. The study received ethical 
approval by the Institutional Review Board. Participants were recruited from the American 
Medical Association (AMA) Physician Masterfile, a database of all licensed U.S. physicians.12 
We did not recruit physicians who: 1) were trainees, 2) were locum tenens, 3) reported their 
major professional activity was non-patient care, 4) were ≥65 years of age, as the AMA 
Masterfile has been shown to have a significant lag in updating retired physicians,13 and 5) listed 
a post office box for their address (precluding use of FedEx mailing). Florida-based pediatric and 
family medicine physicians were sampled based on their proportional representation in the 
Florida physician primary care workforce and randomly selected from the AMA Masterfile.11 
We selected only one physician per group practice and if a provider indicated they did not 
provide care to either males or females between the ages of 9 and 26 they were excluded from 
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analyses. This study was granted a waiver of documentation of informed consent based on the 
following criteria: 1) the only record linking the subject and the research is the consent document 
and the principal risk would be potential harm resulting from a breach of confidentiality; and 2) 
the research presents no more than minimal risk of harm to subjects and involves no procedures 
for which written consent is normally required outside of the research context. 
 
Over the course of two months, our study team mailed one original and up to two reminder 
surveys to our sample. Physicians were given the option to either mail their completed paper 
survey back to our study team or respond via an online link included in the cover letter that 
accompanied the mailed survey. To increase our survey response rate, representatives from the 
Florida Chapter of the American Academy of Pediatrics (FCAAP) and the Florida Academy of 
Family Physicians (FAFP) also sent two emails to their respective membership informing them 
about our study and the importance of their participation.  
 
Measures 
The survey was developed using previously validated items where possible.14-21 The final 41-
item survey assessed three domains: physician characteristics, general clinic characteristics, and 
vaccine-specific characteristics. Physician characteristics included demographic information, 
specialty, state of residency training, and HPV knowledge. General clinic characteristics 
included practice size and location, and demographic characteristics of the patient population. 
Knowledge was measured using 11-items regarding HPV infection, disease, vaccination, and 
guidelines from various organizations (including the World Health Organization and ACIP). One 
point was awarded for each correct response and correct responses were summed to crease a 
knowledge score (range: 0-11). For a full list of variables assessed, see Table 1. Vaccine-specific 
characteristics included whether they administer the vaccine to male and female patients; are a 
VFC provider; whether they use reminder prompts and how many different prompts they use; 
and if they have a vaccine coordinator in their office. 
 
A series of questions assessed whether the physician’s clinic used AFIX-based strategies related 
to HPV vaccination, regardless of whether these activities were the result of a health department 
visit or not, with at least one question assessing each of the AFIX constructs. Assessment was the 
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only construct assessed with two different questions. We asked physicians whether their clinic 
ever reviewed series initiation and completion for male or female patients. Separate questions 
assessed series initiation and completion. For Feedback, physicians indicated whether their clinic 
provided one-time feedback to health care providers regarding their HPV vaccination rates. We 
assessed Incentives by asking the physicians to indicate whether their clinic provided rewards 
based on improved HPV vaccination rates. Finally, eXchange of information was quantified by 
assessing whether the physicians were provided ongoing feedback on their HPV vaccination 
rates. Participants had the option of replying to each question with “yes,” “no,” or “unsure.” The 
two questions examining assessment, along with one question each for feedback, incentives, and 
exchange, resulted in five questions assessing AFIX-based strategies. 
 
Statistical Analysis 
Descriptive statistics of the responses to AFIX-related activities were examined for the total 
sample and then separately for family medicine physicians and pediatricians because preliminary 
analyses showed significant differences on several variables between these two specialties. For 
AFIX-based strategies, due to uneven responses, the sample was dichotomized into those who 
responded “yes” to any one of the five questions used to assess AFIX-related quality 
improvement strategies and those who engaged in none of the components. This was done 
because more than half of participants (60.6%) indicated they did not engage in any AFIX 
activities.  
 
Differences in engagement in at least one AFIX-based strategy were examined by comparing 
pediatric and family medicine practitioners. Those with a specialty of “other” (n=20) were not 
analyzed due to the small sample. Finally, multivariable logistic regression analyses were 
performed for family medicine physicians and pediatricians separately to assess factors 
associated with engagement in AFIX-based strategies. We created a multivariable model using 
backward stepwise selection. In order to obtain the best fit model, a p-value of 0.1 was needed 
for a variable to remain in the final model. The initial models included the following variables: 
physician gender, physician age, physician race, physician ethnicity, years practicing medicine, 
residency location, knowledge score, number of physicians in the clinic, clinic situation, clinic 
arrangement, clinic location, patient population race/ethnicity, daily patient load (includes total 
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number of patients the provider sees in one day), use of EMR, administer vaccine to males, 
administer vaccine to females, VFC provider status, use of reminder prompts, have a vaccine 
coordinator. All analyses were conducted using SPSS v24.   
 
Results 
Of the 770 surveys mailed and 46 were undeliverable resulting in 724 surveys being delivered to 
respondents. Of those, 367 were completed and returned to study staff. After accounting for 16 
duplicate surveys, our overall response rate was 48.5% (351/724). We excluded participants who 
reported they did not provide care to male or female patients between the ages of 9 and 26 (n=8), 
who indicated their primary specialty was geriatrics (n=2), and returned the survey after the close 
of the data collection portion of the study (n=1), resulting in a final analytic sample size of 340. 
Given that the surveys were anonymous, we were unable to determine if there was a difference 
between responders and non-responders on demographic and clinic characteristics. However, we 
compared our analytic sample to the sample of physicians included in the initial recruitment 
mailings on age, gender, and specialty. We found no statistically significant difference between 
the analytic sample and recruited physicians by specialty (p=0.249). While the groups were 
statistically significantly different in age, the analytic sample was only marginally younger than 
the recruited sample (mean age=52.3 vs. 53.7; p=0.008), and the statistical difference was likely 
due to the large sample sizes. Additionally, a difference of only 1.4 years, in practical terms, 
would likely not indicate any training or generational differences between groups. Similarly, 
there was a higher proportion of men in the recruited sample (59.7%) as compared to the analytic 
sample (51.5%). Although statistically significant (p=0.012), this slight difference was unlikely 
to affect results. Furthermore, our previous studies have shown no differences in HPV 
vaccination attitudes by physician gender,11,14 further indicating this slight difference was 
unlikely to affect results. 
 
Characteristics of the total sample, as well as differences between pediatricians and family 
medicine physicians, are presented in Table 1. Briefly, more than half of participants were male 
(52%), White (60%), and/or non-Hispanic (55%). The majority reported their specialty as either 
pediatrics (49%) or family medicine (45%), were VFC providers (52%), and completed their 
residency outside of Florida (68%). Many participants reported their clinic was located in an 
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urban setting (54%), utilized electronic medical records (88%), and had a vaccine coordinator 
(73%). Despite nearly all participants identifying as either pediatricians or family medicine 
physicians and seeing patients 9-26 years old, 28% of physicians reported the HPV vaccine was 
not administered to female patients in their clinic and 33% indicated the HPV vaccine was not 
administered to male patients in their clinic.  
 
AFIX-related components, corresponding survey questions, frequency with which participants 
responded “yes” to the survey items, and differences by specialty are reported in Table 2. For a 
diagrammatic representation of the numbers of people responding “yes” to each AFIX-based 
activity, see the Venn diagram in Figure 1. A minority of physicians (n=134; 39%) reported that 
their clinic utilized at least one AFIX-based activity specific to HPV vaccines. Of the five 
activities assessed, only 19 participants (6%) reported engaging in all of them. A small 
proportion of respondents reported that their clinic had reviewed series initiation (25%) or series 
completion (29%) rates for either adolescent female or male patients. Twenty-two percent 
reported one-time feedback on HPV vaccination rates and 24% reported they were provided 
ongoing feedback on their HPV vaccination rates following implementation of quality 
improvement strategies. Of VFC providers, a group that is targeted for AFIX activities to support 
providers in increasing pediatric vaccination rates, only approximately half (97/176; 55%) 
indicated they engaged in at least one AFIX-related activity related to HPV vaccination. This is 
this is significantly different from the non-VFC providers, of whom, less than a quarter engaged 
in at least one AFIX-based activity (33/138; 23.9%) (p<0.001). There were not significant 
differences by specialty for most of the constructs; however, there was a statistically significant 
difference between family medicine physicians and pediatricians on whether they were provided 
ongoing feedback on their HPV vaccination rates (p<.0001).   
 
Results from the multivariable analyses can be found in Table 3. For pediatricians, two variables 
were significantly associated with engagement in at least one AFIX-based strategy: (1) greater 
HPV-related knowledge (aOR=1.33; 95% CI=1.08-1.63); and (2) use of one reminder prompt 
(aOR=3.61; 95% CI=1.02-12.77) or more than one reminder prompt (aOR=6.59; 95% CI=1.86-
23.37), compared to using no reminder prompts.  
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
11 
 
For family medicine physicians, HPV-related knowledge also positively predicted AFIX-based 
activity (aOR=1.57; 95% CI=1.20-2.05). Other positive predictors were: (1) having a majority of 
patients not non-Hispanic White (aOR=3.02; 95% CI=1.08-8.43); (2) having a typical daily 
patient load of 20-24 patients/day as compared to less than 20/day (aOR=9.05; 95% CI=2.72-
30.10); and (3) administering the HPV vaccine to males in their clinics (aOR=2.98; 95% 
CI=1.11-8.02). 
 
Discussion 
Increasing HPV vaccination rates is of particular importance in Florida, where HPV vaccine 
uptake falls below the national average for both boys and girls.4 Recent research has shown that 
using the evidence-based strategies related to AFIX-activities results in modest increases of HPV 
vaccine uptake.8,22,23 Despite the potential benefits of using AFIX-related quality improvement 
strategies, the majority of participants in our sample reported their clinic did not engage in any of 
the HPV-related AFIX-based activities we measured, even though the majority indicated they 
were VFC providers and should have participated in AFIX visits from the health department.  
 
While engagement in AFIX-related quality improvement strategies was disappointingly low in 
our population, what was perhaps more striking were the rates of physicians who indicated they 
provided care to patients between the ages of 9 and 26, but did not HPV vaccine was not 
administered in their clinic. Indeed, one-third of participants indicated HPV vaccine was not 
administered to male patients in their clinic and over one-fourth of participants indicated it was 
not administered to female patients in their clinic. These low rates of vaccine administration are 
of particular concern. Future research should examine reasons behind this lack of HPV vaccine 
administration as well as possible interventions to increase administration to age-appropriate 
patients.           
 
Pediatricians who do not utilize reminder prompts had lower odds of engaging in at least one 
HPV-related AFIX-based strategy which indicates a group that could be targeted for an 
intervention could be providers with less systems-level support for vaccinations, such as 
reminder systems. HPV-related knowledge was associated with HPV-related AFIX activity 
regardless of specialty and increasing HPV-related knowledge may be a viable means of 
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increasing HPV vaccination itself. Additionally, our results indicated eXchange of information 
was the only construct that significantly differed between specialties. This may indicate that 
while pediatricians and family medicine physicians are receiving similar efforts for most of the 
AFIX-related quality improvement strategies, there is less emphasis in the long-term follow-up 
for family medicine. One possible explanation is that pediatric clinics account for the majority of 
general vaccinations administered24,25 and have more infrastructure for data monitoring programs 
including systems to track undervaccinated children.26 As with all of the variables, it is unclear 
what the temporal association is between HPV knowledge and AFIX-related activities. 
Longitudinal research is needed to elucidate the relationship between these factors.  
 
This study is among the first to examine factors associated with HPV-related AFIX-based 
strategies and it has many strengths. For example, the study featured a randomly-selected, 
statewide sample and physicians’ report of their clinics’ participation in AFIX-related activities. 
However, the results should be interpreted in light of some limitations. The cross-sectional 
survey design precludes the ability to make causal inferences about variables significantly 
associated with AFIX-related activities. The participants surveyed were from a single state and 
therefore their responses may not be generalizable to the broader U.S. physician population. 
However, focusing on one state allowed us to examine AFIX-related activities in a state with 
relatively high rates of HPV-related disease and relatively low rates of HPV vaccination.4,5 
Physicians may have reported socially-desirable responses regarding vaccination behaviors; 
however, the anonymous nature of the survey, as well as the range of responses we received, 
suggest social desirability was minimal. Physicians most in favor of HPV vaccination may have 
been more inclined to complete the survey, possibly providing an overestimate of the proportion 
engaging in AFIX-aligned quality improvement activities. This overestimation of AFIX-related 
activities in our study population serves to underscore the importance of the study findings 
because engagement in AFIX-related activities in a less engaged population is presumably even 
lower. We assessed physicians’ report of whether these HPV-related AFIX-based strategies were 
occurring in their clinic, but we did not assess organizational-level quality improvement 
strategies that may have been occurring and of which physicians may be unaware. Additionally, 
the physicians’ clinics may have engaged in AFIX-related activities that we did not assess, such 
as comparing HPV vaccination rates with other adolescent platform vaccines (meningococcal 
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and Tdap [tetanus, diphtheria, and pertussis]) to highlight missed opportunities in the clinic; 
however, we believe the activities assessed represent the core of the program. Because we 
selected one physician per clinic, there is the possibility the physician we chose did not have the 
same experience with AFIX-based strategies as other physicians in the same practice. However, 
by selecting only one physician per clinic we ensured non-violation of statistical assumptions 
pertaining to independence of responses. Finally, our study was limited to physicians, although 
other health care providers may recommend HPV vaccination. Thus, a study examining AFIX-
related activities and HPV vaccination among other allied health professionals is warranted. 
 
This study adds valuable information regarding HPV vaccination, engagement in AFIX 
activities, and factors associated with AFIX activities in order to identify areas for intervention. 
Future research should include qualitative research methods to better understand reasons why 
there is low utility of AFIX-based strategies. Additionally, future interventions to increase HPV 
vaccination should focus on implementing and evaluating AFIX-based strategies with groups 
that indicated low report of AFIX-related activities: family medicine physicians, physicians 
reporting low HPV-related knowledge, and those who do not have vaccine reminder systems in 
their office.         
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Table 1. Sample characteristics of the Study Population Collected in Florida in 2016 (N=340) 
Physician characteristics Total samplea 
(n=340) 
n (%); m (SD) 
Pediatricians 
(n=160)  
n (%); m (SD) 
Family Medicine 
(n=146)  
n (%); m (SD) 
p-valueb 
Gender    0.002 
Male 171 (51.5) 67 (42.1) 85 (59.9)  
Female 161 (48.5) 92 (57.9) 57 (40.1)  
Age     0.332 
30-44 66 (19.4) 28 (18.1) 35 (25.2)  
45-54 108 (33.3) 53 (34.2) 43 (30.9)  
55-64 150 (46.3) 74 (47.7) 61 (43.9)  
Race    0.305 
White/Caucasian 195 (59.6) 89 (57.1) 88 (62.0)  
Black/African American 23 (7.0) 9 (5.8) 12 (8.5)  
Asian 35 (10.7) 23 (14.7) 12 (8.5)  
Other 74 (22.6) 35 (22.4) 30 (21.1)  
Ethnicity    0.006 
Hispanic 145 (44.9) 81 (51.9) 50 (36.0)  
Non-Hispanic 178 (55.1) 75 (48.1) 89 (64.0)  
Years practicing medicine    <0.001 
15 or fewer 120 (37.7) 39 (25.3) 68 (51.5)  
16-24 112 (35.2) 58 (37.7) 40 (30.3)  
25 or more 86 (27.0) 57 (37.0) 24 (18.2)  
State completed residency     0.837 
Florida 102 (31.8) 51 (32.7) 45 (33.8)  
Other 219 (68.2) 105 (67.3) 88 (66.2)  
Clinical specialty     
Pediatrics 160 (49.1)    
Family Medicine 146 (44.8)    
Otherc 20 (6.1)    
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
18 
 
HPV knowledge (range 0-11) 4.2 (2.3) 4.9 (2.1) 3.9 (2.2) <0.001 
General clinic characteristics Total sample 
 
Pediatricians 
(n=160)  
n (%); m (SD) 
Family Medicine 
(n=146)  
n (%); m (SD) 
p-value 
HPV-specific AFIX activities    0.063 
No AFIX Activities 206 (60.6) 84 (52.5) 92 (63.0)  
At least 1 AFIX Activity 134 (39.4) 76 (47.5) 54 (37.0)  
Number of physicians    0.143 
1 105 (32.0) 47 (29.7) 52 (35.6)  
2-5 48 (14.6) 21 (13.3) 24 (16.4)  
6-15 162 (49.4) 87 (55.1) 63 (43.2)  
16 or more 13 (4.0) 3 (1.9) 7 (4.8)  
Clinic situation    0.004 
Single specialty 234 (70.9) 125 (79.1) 92 (64.3)  
Multi-specialty 81 (24.5) 31 (19.6) 41 (28.7)  
Other 15 (4.5) 2 (1.3) 10 (7.0)  
Clinic arrangement    0.065 
Full or part owner 170 (51.5) 91 (58.0) 68 (47.6)  
Employee of physician-
owned practice 
62 (18.8) 34 (21.7) 24 (16.8)  
Employee of 
hospital/hospital system 
38 (11.5) 11 (7.0) 22 (15.4)  
Employee of a group or 
HMO 
16 (4.8) 7 (4.5) 6 (4.2)  
Employee of hospital, clinic, 
or university 
28 (8.5) 10 (6.4) 16 (11.2)  
Other 16 (4.8) 4 (2.5) 7 (4.9)  
Clinic location    0.282 
Urban 178 (53.8) 90 (57.3) 69 (48.3)  
Suburban 116 (35.0) 51 (32.5) 55 (38.5)  
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Rural/Other 37 (11.2) 16 (10.2) 19 (13.3)  
Race/ethnicity of patients    <0.001 
Non-Hispanic White 140 (42.4) 49 (31.4) 78 (54.5)  
Otherd  190 (57.6) 107 (68.6) 65 (45.5)  
Typical daily patient load    <0.001 
Less than 20 99 (29.8) 38 (24.1) 48 (33.6)  
20-24 93 (28.0) 36 (22.8) 51 (35.7)  
25 or more 140 (42.2) 84 (53.2) 44 (30.8)  
Use EMR?    0.028 
Yes 296 (88.4) 133 (84.2) 133 (92.4)  
No 39 (11.6) 25 (15.8) 11 (7.6)  
Vaccine specific 
characteristics 
Total sample 
 
Pediatricians 
(n=160)  
n (%); m (SD) 
Family Medicine 
(n=146)  
n (%); m (SD) 
p-value 
Administer the HPV vaccine to 
males 
   <0.001 
No 113 (33.3) 13 (8.1) 76 (52.1)  
Yes 226 (66.7) 147 (91.9) 70 (47.9)  
Administer the HPV vaccine to 
females  
   <0.001 
No 94 (27.6) 9 (5.6) 63 (43.2)  
Yes 246 (72.4) 151 (94.4) 83 (56.8)  
VFC provider    <0.001 
Yes 176 (52.2) 135 (84.9) 34 (23.4)  
No 138 (40.9) 23 (14.5) 93 (64.1)  
I don’t know  23 (6.8) 1 (0.6) 18 (12.4)  
HPV reminder prompts used    0.002 
Didn’t use any reminders 98 (28.8) 29 (18.1) 51 (34.9)  
Used one reminder 129 (37.9) 63 (39.4) 54 (37.0)  
Used more than 1 reminder 113 (33.2) 68 (42.5) 41 (28.1)  
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Have vaccine coordinator    <0.001 
Yes 243 (73.0) 143 (90.5) 85 (59.4)  
No 81 (24.3) 13 (8.2) 54 (37.8)  
I don’t know 9 (2.7) 2 (1.3) 4 (2.8)  
Abbreviations: HPV (human papillomavirus), AFIX (assessment, feedback, incentives, exchange 
of information), HMO (health maintenance organization), EMR (electronic medical record), 
VFC (vaccines for children) 
aPercentages in this column do not include missing data. Less than 6% of data on any given 
variable was missing.  
bp-value indicates the statistical difference between family medicine physicians and pediatricians 
c“Other” category for physician specialty includes: internal medicine, general practice, urgent 
care/emergency medicine, pediatric subspecialties, adult-only family medicine, 
allergy/immunology  
d“Other” category for patient race/ethnicity includes: Non-Hispanic Black (n=25), Hispanic 
(n=102), Native American/Alaska Native (n=2), other/multiracial (n=14), and no definable 
majority (n=47) 
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Table 2: AFIX Components and Corresponding Frequency of Participants Responding “Yes” to Each Survey Item (n=134)a 
CDC’s AFIX Components Corresponding Survey Questions Total 
n (%) of 
Participants 
Responding 
“Yes”b 
Pediatricians 
n (%) of 
Participants 
Responding 
“Yes” 
Family Medicine 
n (%) of 
Participants 
Responding 
“Yes” 
p-
valuec 
 Has your practice ever done any of 
the following specific to HPV 
vaccination? (yes, no, unsure) 
    
Assessment of the healthcare 
provider's vaccination coverage 
levels and immunization practices. 
Reviewed series initiation rates for 
either adolescent males or females 
 
84 (24.7) 46 (28.8) 36 (24.7) 0.419 
Reviewed series completion rates for 
either adolescent males or females 
98 (28.8) 57 (35.6) 39 (26.7) 0.093 
Feedback of results to the provider 
along with recommended quality 
improvement strategies to improve 
processes, immunization practices, 
and coverage levels. 
Provided one‐time feedback to 
health care providers regarding HPV 
vaccination rates 
76 (22.4) 43 (26.9) 31 (21.2) 0.250 
Incentives to recognize and reward 
improved performance. 
Provided rewards to providers based 
on improved HPV vaccination rates 
26 (7.6) 14 (8.8) 10 (6.8) 0.537 
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eXchange of information with 
providers to follow-up on their 
progress towards quality 
improvement in immunization 
services and improvement in 
immunization coverage levels. 
Provided ongoing feedback on their 
HPV vaccination rates after quality 
improvement strategies were 
implemented 
82 (24.1) 56 (35.0) 24 (16.4) <0.001 
Total responding “yes” to at least 
one of the above 
 134 (39.4) 76 (47.5) 54 (37.0) 0.063 
aParticipants were excluded from the table if they indicated they did not engage in any AFIX-related activities (n=206)  
bThe “total” column includes even those participants who indicated their specialty was “other” or missing. 
cp-value indicates the statistical difference between family medicine physicians and pediatricians 
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Table 3. Predictors of AFIX activity stratified by specialty (n=206)a,b  
 
Pediatricians 
Multivariable 
aOR (95% CI) 
(n=160) 
Family Medicine 
Multivariable  
aOR (95% CI) 
(n=146) 
HPV knowledge (range 0-11) 1.33 (1.08-1.63) 1.57 (1.20-2.05) 
Race of patients   
Non-Hispanic White  (ref.) 
Other  3.02 (1.08-8.43) 
Typical daily patient load   
Less than 20  (ref.) 
20-24  9.05 (2.72-30.10) 
25 or more  1.66 (0.48-5.70) 
Administer the vaccine to males   
No  (ref.) 
Yes  2.98 (1.11-8.02) 
Reminder prompts used   
Didn’t use any reminders (ref.)  
Used one reminder 3.61 (1.02-12.77)  
Used more than 1 reminder 6.59 (1.86-23.37)  
aThe following variables were included as potential covariates for both models: physician gender, 
physician age, physician race, physician ethnicity, years practicing medicine, residency location, 
knowledge score, number of physicians in clinic, clinic situation, clinic arrangement, clinic location, 
patient population race/ethnicity, daily patient load, use of EMR, administer vaccine to males, administer 
vaccine to females, VFC provider status, use of reminder prompts, have a clinic vaccine coordinator.     
bFor both models we used backward stepwise regression with a significance level of 0.1 to stay in the 
model. 
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Figure 1. Distribution of Participants Answering “Yes” to Engaging in Each Activity 
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Highlights: 
 
 The AFIX program uses evidence-based strategies to increase childhood vaccinations. 
 Engagement in HPV-specific AFIX activities was low in this population. 
 This study identified factors associated with engagement in HPV-related AFIX activities. 
 Understanding these factors helps to target populations for future interventions.  
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